Disposition, elimination and haemodynamic effects of verapamil and trandolapril in patients with fatty liver disease

Clinical Drug Investigation

Volumn 14, Issue 5, 1997, Pages 376-382

  Siepmann, Martin ^a   Rao, Boinpally Ramesh ^a   Kirch, Wilhelm ^a  

^a DRESDEN UNIVERSITY OF TECHNOLOGY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; TRANDOLAPRIL; VERAPAMIL;

ADULT; AGED; ANGINA PECTORIS; AREA UNDER THE CURVE; ARTICLE; ATRIOVENTRICULAR BLOCK; BLOOD PRESSURE; BRADYCARDIA; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG DISPOSITION; DRUG ELIMINATION; DRUG HALF LIFE; DRUG MIXTURE; ELECTROCARDIOGRAM; FATIGUE; FATTY LIVER; FEMALE; HEART RATE; HEMODYNAMICS; HUMAN; HYPERTENSION; LIVER FUNCTION; MALE; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; SUSTAINED RELEASE PREPARATION;

EID: 0030671458     PISSN: 11732563     EISSN: None     Source Type: Journal    
DOI: 10.2165/00044011-199714050-00006     Document Type: Article

References (24)

1. Reid JL. First-line and combination treatment for hypertension. Am J Med 1989; 86 Suppl. 4A: 2-5
2. Hamann SR, Blouin RA, McAllister Jr RG. Clinical pharmacokinetics of verapamil. Clin Pharmacokinet 1984; 9: 26-41
3. Arner P, Wade A, Engfeldt P, et al. Pharmacokinetics and pharmacodynamics of trandolapril after repeated administration of 2mg to young and elderly patients with mild-to-moderate hypertension. J Cardiovasc Pharmacol 1994; 23 Suppl. 4: 44-9
4. Somogyi A, Albrecht M, Kliems G, et al. Pharmacokinetics, bioavailability and ECG response of verapamil in patients with liver cirrhosis. Br J Clin Pharmacol 1981; 12: 51-60
5. Wiseman LR, McTavish D. Trandolapril. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in essential hypertension. Drugs 1994; 48: 71-90
6. Echizen H, Eichelbaum M. Clinical pharmacokinetics of verapamil, nifedipine and diltiazem. Clin Pharmacokinet 1986; 11: 425-49
7. Lenfant B, Mouren M, Bryce T, et al. Trandolapril: pharmacokinetics of single oral doses in healthy male volunteers. J Cardiovasc Pharmacol 1994; 23 Suppl. 4: 38-43
8. Eichelbaum M, Somogyi A. Rapid and sensitive method for the determination of antipyrine in biological fluids by high liquid chromatography. J Chromatogr 1977; 140: 288-92
9. Sachs L, editor. Angewandte Statistik. Berlin: Springer Verlag, 1992
10. Eichelbaum M, Mikus G. Pharmacokinetics, bioavailability, cardiovascular and biochemical effects of gallopamil in patients with liver cirrhosis and in healthy subjects without liver disease. Stuttgart (Germany): Dr M. Fischer-Bosch-Institut für Klinische Pharmakologie; 1992 Internal Report
11. Dylewicz P, Kirch W, Santos SR, et al. Bioavailability and elimination of nitrendipine in liver disease. Eur J Clin Pharmacol 1987; 32: 563-8
12. Kleinbloesem CH, Van Harten J, Wilson JPH, et al. Nifedipine: kinetics and hemodynamic effects in patients with liver cirrhosis after i.v. and oral administration. Clin Pharmacol Ther 1986; 40: 21-8
13. Lasseter KC, Shambleu EC, Murdoch AA, et al. Steady state pharmacokinetics of nitrendipine in hepatic insufficiency. J Cardiovasc Pharmacol 1984; 6 Suppl. 7: 977-81
14. Branch RA, James J, Read AE. A study of factors influencing drug disposition in chronic liver disease, using the model (+)-propranolol. Br J Clin Pharmacol 1976; 3: 243-9
15. Kirch W, Halabi A, Nokhodian A. Disposition and elimination of bunazosin in chronic liver disease and renal insufficiency. Eur J Drug Metab Pharmacokinet 1993; 18: 309-13
16. Kirch W, Rose I, Demers HG, et al. Pharmacokinetics of bisoprolol during repeated oral administration to healthy volunteers and patients with kidney or liver disease. Clin Pharmacokinet 1987; 13: 110-3
17. Todd PA, Heel RC. Enalapril: a review of its pharmacodynamic and pharmacokinetic properties and therapeutic use in hypertension and congestive heart failure. Drugs 1986; 31: 198-248
18. Vesell ES, Passananti GT, Glenwright PA, et al. Studies on the disposition of antipyrine, aminopyrine, and phenacetin using plasma, saliva and urine. Clin Pharmacol Ther 1975; 18: 259-72
19. Andreasen PB, Vesell ES. Comparison of plasma levels of antipyrine, tolbutamide, and warfarin after oral and intravenous administration. Clin Pharmacol Ther 1974; 16: 1059-65
20. Andreasen PB, Ranek L, Statland BE, et al. Clearance of antipyrine-dependence of quantitative liver function. Eur J Clin Invest 1974; 2: 129-34
21. McAllister RG, Kirsten EB. The pharmacology of verapamil. IV. Kinetic and dynamic effects after single intravenous and oral doses. Clin Pharmacol Ther 1982; 31: 418-26
22. Woodcock BG, Schulz W, Kober G, et al. Direct determination of hepatic extraction of verapamil in cardiac patients. Clin Pharmacol Ther 1981; 30: 52-6
23. Kaim AAH, Farker K. Pharmacokinetics and pharmacodynamics of gallopamil in patients with liver cirrhosis [abstract no. 36]. Naunyn-Schmiedebergs Arch Pharmacol 1992; 345 Suppl.: R9
24. Siepmann M, Boinpally Ramesh R, Kirch W. Disposition, elimination and haemodynamic effects of gallopamil in patients with fatty liver disease. Clin Drug Invest 1995; 10: 337-43